The U.S. Supreme Court docket has reportedly chosen to not overview Vanda Prescription drugs Inc’s VNDA try to revive patents for its sleep-disorder treatment Hetlioz, which had beforehand been invalidated in a authorized battle with generic drugmakers Teva Pharmaceutical Industries Restricted TEVA and Apotex.
Vanda had filed a lawsuit in 2018 towards Teva and Apotex in Delaware, alleging patent infringement after they sought approval to fabricate generic variations of Hetlioz, Reuters famous.
The Federal Circuit, a patent-focused courtroom, dominated towards Vanda, resulting in the corporate’s attraction to the Supreme Court docket, which was declined.
Additionally Learn: Neuropsychiatric-Targeted Vanda Prescription drugs Rejects Future Pak’s Takeover Bid Valued Up To $7.75/Share.
This choice marks the Supreme Court docket’s avoidance of addressing when a patent will be invalidated as “apparent,” a matter not revisited since 2007, as per the report.
Final yr, a federal courtroom granted last judgment in favor of Vanda Prescription drugs’ Freedom of Data Act (FOIA) case requesting data created by the FDA whereas reviewing Vanda’s utility in search of approval of Hetlioz (tasimelteon).
Vanda’s annual income from Hetlioz gross sales surpassed $100 million in 2023.
Nonetheless, the corporate confronted setbacks in its authorized battle, with U.S. District Choose Colm Connolly ruling towards Vanda in 2022, declaring its patents invalid primarily based on numerous elements together with medical trial outcomes and FDA steerage.
The Federal Circuit upheld this choice in 2023, prompting Vanda’s attraction to the Supreme Court docket earlier this yr.
Vanda argued that the Federal Circuit’s normal for obviousness deviates from Supreme Court docket precedents, probably rendering many drug improvement developments unpatentable, significantly impacting therapies for uncommon ailments.
In response, Teva and Apotex contended that Vanda’s attraction was an try to increase its patent monopoly on Hetlioz, asserting that the case merely concerned the appliance of settled obviousness regulation.
Worth Motion: VNDA shares are down 4.21% at $4.89 on the final examine Monday.
Disclaimer: This content material was partially produced with the assistance of AI instruments and was reviewed and revealed by Benzinga editors.
Picture Through Shutterstock
